Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
相关临床试验
8
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
12.5%
Available
1
12.5%
已完成
1
12.5%
招募中
5
62.5%
暂无批准数据
- The FDA faces a packed July 2026 with PDUFA dates for therapies targeting hepatocellular carcinoma, multiple myeloma, IgA nephropathy, and advanced breast cancer. - Elevar Therapeutics' rivoceranib plus camrelizumab could become a new first-line option for unresectable hepatocellular carcinoma based on phase 3 CARES-310 trial data. - Vera Therapeutics seeks accelerated approval for atacicept in IgA nephropathy after the ORIGIN phase 3 trial met its primary endpoint of reduced proteinuria at week 36. - MannKind's FUROSCIX ReadyFlow Autoinjector, delivering subcutaneous furosemide in under 10 seconds, faces a July 26 decision for edema in chronic heart failure and CKD.
- Tang Capital Management initiated a new $56.8 million position in Celcuity Inc., purchasing nearly 1.2 million shares in the third quarter of 2024. - The investment follows Celcuity's potentially "practice-changing" Phase 3 results for gedatolisib in breast cancer, with FDA submission expected by year-end. - Celcuity's stock has surged 672% over the past year, reaching $97.50 per share and a market capitalization of $4.5 billion. - The company maintains $455 million in liquidity to fund operations through 2027 as it prepares for potential commercialization of its lead cancer therapy.
- Celcuity's Phase 1 trial of gedatolisib combined with darolutamide achieved a median radiographic progression-free survival of 9.1 months in men with metastatic castration-resistant prostate cancer. - The combination therapy demonstrated a 67% six-month progression-free survival rate with favorable tolerability, as no patients discontinued treatment due to adverse events. - The company is advancing to Phase 1/1b dose optimization studies to determine the recommended Phase 2 dose for this novel PI3K/mTOR inhibitor combination.
- Celcuity has upsized its senior secured credit facility to $500 million with Innovatus Capital Partners and Oxford Finance, including $350 million in committed capital and up to $150 million at mutual discretion. - The financing follows positive topline data from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 Phase 3 clinical study evaluating gedatolisib in advanced breast cancer patients. - The enhanced financial structure provides funding for the rolling NDA submission to FDA via the RTOR program and commercial launch preparations for gedatolisib. - Additional milestone-based funding includes $100 million upon FDA approval of gedatolisib for second-line wild-type advanced breast cancer patients and $120 million upon achieving commercial revenue milestones.
- Celcuity received US Patent No. 12,350,276 covering the clinical dosing regimen for gedatolisib in ER+/HER2- breast cancer patients, extending patent exclusivity to 2042. - The company's worldwide gedatolisib patent portfolio now includes 13 granted US patents and 290 patents in foreign jurisdictions, providing comprehensive intellectual property protection. - Topline data from the VIKTORIA-1 Phase 3 trial evaluating gedatolisib in HR+/HER2- advanced breast cancer is expected in Q3 and Q4 2025 for different patient cohorts.
- Celcuity reported a 66% six-month radiographic progression-free survival rate for gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer patients. - The combination therapy achieved a 43% objective response rate in heavily pretreated HER2+ metastatic breast cancer patients who received at least three prior anti-HER2 therapies. - No patients discontinued gedatolisib due to treatment-related adverse events in either clinical trial, demonstrating favorable tolerability profiles. - The company plans to explore higher doses of gedatolisib in prostate cancer patients based on pharmacokinetic data suggesting a dose-efficacy relationship.
- Phase 1b trial demonstrates gedatolisib combination therapy achieved 77.3 months median overall survival in treatment-naïve HR+/HER2- advanced breast cancer patients. - In patients previously treated with CDK4/6 inhibitors, the gedatolisib combination showed a median overall survival of 33.9 months, comparing favorably to current standard-of-care regimens. - Results support Celcuity's ongoing VIKTORIA-1 and planned VIKTORIA-2 Phase 3 trials evaluating gedatolisib's triple pathway blockade strategy in advanced breast cancer.
- Gedatolisib, a dual PI3K/mTOR inhibitor developed by Celcuity, shows promising market potential with projected annual revenue of $155 million by 2034 in the US market. - The drug is being evaluated across multiple solid tumors, including ER+/HER2-negative metastatic breast cancer, prostate cancer, and various gynecological cancers. - Celcuity reported increased investment in R&D, with operating losses expanding from $39.4M in FY2022 to $66.2M in FY2023, reflecting intensive development efforts.
